J&J new social media series supports and celebrates ‘warrior’ nurses in pulmonary hypertension
During the pandemic, conversations often focused on supporting healthcare workers on the frontline. Now Johnson & Johnson’s Janssen is offering support to a different kind of “PHrontline” worker — nurses who care for pulmonary hypertension, or PH, patients.
Janssen’s “PHrontline Conversations” debuted last week on Facebook Live with the first episode, in a planned series, on managing care and up-to-date education on the rare high blood pressure condition. While typical hypertension is high blood pressure in the arteries throughout the body, PH is specific to the lungs.
PHrontline brings together experienced and new PH nurses, along with experts, from around the country to compare notes and best practices and build community. The Facebook event was live last Thursday but remains available for repeat or new viewers and has since gotten 400 views, said Howard Reid, VP of marketing for pulmonary hypertension at Janssen.
“Nurses in the community may see only a few PH patients a year so staying up to date on best practices in the care and treatment of patients is really important,” he said. “We also want to celebrate and recognize these nurses. … They are warriors. They don’t let anything get in their way to do everything in their power to help these patients live the best quality life possible.”
During the kickoff event, two topics emerged as central to PH and nursing. The first was the complexity in treating the disease, which was not surprising considering not only the nuances of the rare condition itself but also the challenges in diagnosing and treating it during the pandemic.
“Many patients were concerned about going to the hospital or going to the doctor so virtual care for patients with PH was a really interesting topic,” Reid said. “The nurses shared different approaches to patient management during the pandemic and now that hopefully, we’re moving to a different stage, how they’re coming out of it and encouraging patients to return to care.”
The second topic, risk assessment, is an ongoing conversation in PH. While there are recommended guidelines for objective risk assessments, they’re not always followed, Reid said. Healthcare providers who have decades of experience or have seen many PH patients, still use their intuition in diagnosing.
Janssen is looking to change that paradigm by driving awareness and education around PH patients.
“Treating PH is a multidisciplinary approach,” Reid said. “But nurses play a critical role in helping patients get started with their therapy as well as the management with their disease long term,” adding that “oftentimes patients will call the nurse if they’re having a particularly challenging day to get advice on how to best manage their PH.”
Janssen has also adopted a broader approach for PH and PAH, a more specific pulmonary arterial hypertension, to drive general awareness of the conditions. Patients, for example, share PH and PAH experiences on the Janssen “With Me” website, with some promoted in JanssenUS social media posts.
The awareness work is unbranded, but J&J does market Uptravi — approved to treat pulmonary arterial hypertension.